Phase 2 RCT in 104 patients with HR+/HER2- metastatic breast cancer: adding pembrolizumab to sacituzumab govitecan did not significantly improve median PFS (8.4 vs 6.7 months; HR 0.76, 95% CI 0.48-1.19, P=0.12). Overall survival also did not differ significantly.
RCTn = 104
Garrido-Castro et al. SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer